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Regarding “A comparative evaluation of
polytetrafluoroethylene, umbilical vein, and
saphenous vein bypass grafts for femoral-popliteal
above-knee revascularization: a prospective
randomized Department of Veterans Affairs
cooperative study”
To the Editors:
Johnson et al1 report the fourth published series of patients
requiring lower limb revascularization and undergoing a protocol
of prospective randomization to saphenous vein, umbilical vein,
or PTFE. Eickoff et al2 reported on 104 below-knee popliteal
procedures, Aalders and von Vroonhoven3 on 96 above-knee
popliteal bypasses, and McCollum et al4 on 191 patients with an
above-knee: below-knee ratio of 2:1. All of these data were accu-
mulated and, with the exception of the delayed report by Johnson
et al,1 reported in the 1980s. Several comments are in order:
1. Though these studies are dated and in many areas, flawed,
they are, nonetheless, incredibly, the only ones carried out
with more than one alternative to the saphenous vein, ran-
domized, prospective, and performed at multiple surgical
sites. This is in contradiction to the manuscript by Burger et
al,5 which typifies the usual reporting of lower limb graft
material reviews—a single graft compared with autologous
vein, the usual inferior results obtained with a prosthetic and
the standard conclusion that, despite differences in patency,
use of the prosthetic is “reasonable” and “acceptable.” The
Invited Comment by J. Mills,6 which should be required
reading for all vascular surgeons, points to the deficiencies of
statistical analysis in Burger’s paper1 and others based on
inadequate power.
2. The Meadox product used in all these studies is no longer
manufactured. The currently available UV graft is manufac-
tured by BioVascular Inc, Minn. There are available data7,8
showing absence of aneurysmal degradation with the latter
product as well as a significant reduction in the early throm-
botic events as documented by Johnson et al1 with the
Meadox product. This is based on improved quality control
during manufacture, reduction of residual aldehyde moities in
graft and storage media, and appreciation of the surgical skills
required for implantation. Our first decade of experience with
the UV graft was reported in 1988, not in 1998 (reference 20
in Johnson et al1). Additional experience and even better
results with the improved UV graft were reported in 19957
and 1996.8
3. Current evaluations of graft materials should include intraop-
erative completion duplex sonography and be complimented,
as required, with completion angiography. This is the only way
to establish the different materials and surgeons on an even
keel.
4. The ultimate test for comparative function of materials is in
the crural position. No such studies have been performed in
a multihospital, randomized prospective manner and with
more than one alternative material to the saphenous vein.
The Advisory Council for Vascular Surgery to the American
College of Surgeons has recently authorized the formulation
of such a protocol. Its execution will depend on availability
of funding from agencies, foundations, and industry.
Hopefully, this will occur and provide some needed guidance
in a field now clouded by personal bias and the industrial
complex.
Herbert Dardik, MD
Englewood Hospital and Medical Center
Englewood, NJ
REFERENCES
1. Johnson WC, Lee KK, et al. A comparative evaluation of polytetraflu-
oroethylene, umbilical vein, and saphenous vein bypass grafts for
femoral-popliteal above-knee revascularization: a prospective random-
ized Department of Veterans Affairs cooperative study. J Vasc Surg
2000;32:268-77.
2. Eickoff JH, Broome A, Ericcson BF, et al. Four years’ results of a
prospective randomized clinical trial comparing PTFE and human
umbilical vein for below-knee femoropopliteal bypass surgery. J Vasc
Surg 1987;6:506-11.
3. Aalders GJ, van Vroonhoven TJ. PTFE versus human umbilical vein
in above-knee femoropopliteal bypass: results of a randomized clinical
trial. J Vasc Surg 1992;16:816-24.
4. McCollum C, Kenchington G, Alexander C, Franks P, Greenhaigh R.
PTFE or HUV for femoro-popliteal bypass: a multi-center trial. Eur J
Vasc Surg 1991;5:435-44.
5. Burger DHC, Kappetein AP, van Bockel JH, Breslau PJ. A prospec-
tive randomized trial comparing vein with polytetrafluoroethylene in
above-knee femoropopliteal bypass grafting. J Vasc Surg 2000;32:
278-83.
6. Mills JL. P values may lack power: the choice of conduit for above-
knee femoropopliteal bypass graft. J Vasc Surg 2000;32:402-5.
7. Dardik H. The second decade of experience with the umbilical vein
graft for lower-limb revascularization . Cardiovasc Surgery 1995;3:
265-9.
8. Dardik H, Silvestri F, Alasio T, Berry S, Kahn M, Ibrahim I, et al.
Improved method to create the common ostium variant of the distal
arteriovenous fistula for enhancing crural prosthetic graft patency. J
Vasc Surg 1996;24:240-8.
24/41/112315
doi:10.1067/mva.2001.112315
Reply
We welcome comments from the vascular community about
our recently published article on the comparative performance of
saphenous vein, PTFE, and HUV bypasses that were implanted
between 1983 and 1988 and followed until October 1991.1 Dr
Dardik is correct that the HUV bypasses were provided by
Meadox and not by BioVascular. We apologize for the incorrect
citation of his 1988 article (wrong year but correct volume of
Journal of Vascular Surgery).
We concur with Dr Mill’s2 and Dr Dardik’s comments that
the Burger report3 has inadequate “power” and inappropriately
suggests a similar vein and PTFE bypass performance (P = .065)
at 104 weeks’ follow-up (81% primary patency for vein as com-
pared with 67% for PTFE). Note that in our report,1 the 2-year
assisted primary patency was 80.7% in the vein group as compared
with 69.4% in the PTFE group, results that were very similar to
those of Burger but with more patients and longer follow up were
significantly different (P = .03).
The major question raised by Dr Dardik’s letter is whether a
new but similar randomized study needs to be performed in the
21st century with special postoperative duplex surveillance for
patency and aneurysmal formation. I certainly endorse such an
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